Memphasys Limited (ASX:MEM)

Andrew has served as a Director on the Memphasys Ltd Board since March 2012.

Andrew is an entrepreneur with a wealth of business and commercial experience who has successfully established several businesses throughout his career in Australia and New Zealand. With extensive experience in Commercial Property Investment, Andrew is currently involved in the management of his substantial commercial property interests in New Zealand. Andrew has been a significant shareholder in Memphasys for many years.

Edwards brings over 30 years of experience in financial services and corporate governance, aiming to steer Memphasys towards global commercialisation of its sperm separation technology and RoXsta™ System. These advancements are set to strengthen Memphasys’ position in the fertility and biotechnology markets.

David holds a PhD in Pharmacokinetics and is a published researcher. He has presented at international conferences and worked in drug discovery, clinical project management, clinical pathology, business development and operations at senior levels. He has led local and international clinical trials across all phases and has spent the last 10 years developing medico-commercial strategy to facilitate the launch of new products into the Australian market.

David has also spent several years in the animal health sector, where he engaged with key opinion leaders (KOLs) to build relationships and facilitate the success of new products. Given Memphasys’s focus on both human and animal fertility, his combined experience in human pharmaceuticals and animal health equips him with a comprehensive understanding and a strong foundation to further develop the Memphasys business, brand and commercialise the growing pipeline.

Mr Mikel brings to the Board a strong and diverse track record in business development, commercial leadership, capital markets, and strategic partnership execution across the Medtech, diagnostics, healthcare services, and life sciences sectors. He has heldsenior executive and board positions in both listed and private companies, with extensive experience in the commercialisation of disruptive technologies and scaling ventures in regulated markets.

He is currently the CEO and Managing Director of Vitasora Health Limited (ASX: VTS), an ASX-listed remote patient monitoring (RPM) company operating in the U.S. healthcare system. Under his leadership, the company has pioneered the commercialisation of a novel respiratory monitoring device and successfully transitioned into a full-service RPM provider. Mr Mikel led capital raises, secured major U.S. ACO and payer contracts, and executed the cross-border acquisition of U.S.-based Orb Health, expanding the company’s footprint and capabilities in the U.S. market.

Previously, Mr Mikel founded Healthy Sleep Solutions, building it into Australia’s largest sleep health provider before securing ResMed as a strategic investor and leading a successful trade sale to global multinational Air Liquide. He also held senior commercial roles with IMS Health, Merck Sharp & Dohme, Pharmacia, and Searle, with responsibilities across Australia, Asia-Pacific, and Europe.

Importantly, Mr Mikel is familiar with Memphasys and its strategic vision, having previously served as a Non-Executive Director of the Company from June 2018 to March 2020, including as Chair of both the Audit & Risk Committee and the Nomination & Remuneration Committee.

Mr Watkins is a Chartered Accountant and member of the Governance Institute of Australia with extensive ASX experience across biotechnology, bioscience, resources, and information technology sectors. He specialises in ASX statutory reporting, compliance, corporate governance, and board and secretarial support. Mr Watkins serves as Company Secretary for several ASX-listed entities and is currently the SEA Regional Practice Lead & Australia Market Lead at Vistra (Australia) Pty Ltd, a global corporate services provider supporting clients in the Fund, Corporate, Capital Markets, and Private Wealth sectors.